OBJECTIVE: To explore the impact of highly active antiretroviral therapy (HAART) on the prevention of AIDS-defining cancers relative to other AIDS-defining events. DESIGN: Prospective cohort study using 2,121 HIV+ male seroconverters (median age: 28 years, 51% white/non-Hispanic) in the Tri-Service AIDS Clinical Consortium (n = 1694) and the Multicenter AIDS Cohort Study (n = 427). METHODS: Poisson regression models, with calendar periods to represent antiretroviral therapy, were extended to analyze first incident AIDS-defining cancers and other first AIDS-defining events as competing risks. RESULTS: Eighty-one AIDS-defining cancers (64 Kaposi sarcomas; 17 non-Hodgkin lymphomas) and 343 other AIDS events occurred during 14,483 person-years in 1990-2006. The rate ratio of AIDS-defining cancers during the HAART calendar period was 0.26 (95% confidence limits: 0.15, 0.46) and of other AIDS-defining events was 0.28 (95% confidence limits: 0.21, 0.36) compared with the monotherapy/combination therapy calendar period, adjusting for age, infection duration, race, and cohort. The association of HAART with decreased AIDS incidence seemed to be equal (interaction ratio = 0.95 (95% confidence limits: 0.51, 1.74) for AIDS-defining cancers and other AIDS-defining events. CONCLUSIONS: In human immunodeficiency virus-infected men, HAART seems equally protective against first AIDS-defining cancers and other first AIDS-defining events.
OBJECTIVE: To explore the impact of highly active antiretroviral therapy (HAART) on the prevention of AIDS-defining cancers relative to other AIDS-defining events. DESIGN: Prospective cohort study using 2,121 HIV+ male seroconverters (median age: 28 years, 51% white/non-Hispanic) in the Tri-Service AIDS Clinical Consortium (n = 1694) and the Multicenter AIDS Cohort Study (n = 427). METHODS: Poisson regression models, with calendar periods to represent antiretroviral therapy, were extended to analyze first incident AIDS-defining cancers and other first AIDS-defining events as competing risks. RESULTS: Eighty-one AIDS-defining cancers (64 Kaposi sarcomas; 17 non-Hodgkin lymphomas) and 343 other AIDS events occurred during 14,483 person-years in 1990-2006. The rate ratio of AIDS-defining cancers during the HAART calendar period was 0.26 (95% confidence limits: 0.15, 0.46) and of other AIDS-defining events was 0.28 (95% confidence limits: 0.21, 0.36) compared with the monotherapy/combination therapy calendar period, adjusting for age, infection duration, race, and cohort. The association of HAART with decreased AIDS incidence seemed to be equal (interaction ratio = 0.95 (95% confidence limits: 0.51, 1.74) for AIDS-defining cancers and other AIDS-defining events. CONCLUSIONS: In human immunodeficiency virus-infectedmen, HAART seems equally protective against first AIDS-defining cancers and other first AIDS-defining events.
Authors: M P Carrieri; C Pradier; P Piselli; M Piche; E Rosenthal; P Heudier; J Durant; Diego Serraino Journal: Int J Cancer Date: 2003-01-01 Impact factor: 7.396
Authors: Lauren E Cain; Stephen R Cole; Joan S Chmiel; Joseph B Margolick; Charles R Rinaldo; Roger Detels Journal: Am J Epidemiol Date: 2005-12-21 Impact factor: 4.897
Authors: S J Gange; Y Barrón; R M Greenblatt; K Anastos; H Minkoff; M Young; A Kovacs; M Cohen; W A Meyer; A Muñoz Journal: J Epidemiol Community Health Date: 2002-02 Impact factor: 3.710
Authors: S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl Journal: N Engl J Med Date: 1997-09-11 Impact factor: 91.245
Authors: Eric A Engels; Ruth M Pfeiffer; James J Goedert; Phillip Virgo; Timothy S McNeel; Steven M Scoppa; Robert J Biggar Journal: AIDS Date: 2006-08-01 Impact factor: 4.177
Authors: Anna E Coghill; Ruth M Pfeiffer; Meredith S Shiels; Eric A Engels Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-06-15 Impact factor: 4.254
Authors: Brian K Agan; Anuradha Ganesan; Morgan Byrne; Robert Deiss; Christina Schofield; Ryan C Maves; Jason Okulicz; Xiuping Chu; Thomas O'Bryan; Tahaniyat Lalani; Karl Kronmann; Tomas Ferguson; Merlin L Robb; Timothy J Whitman; Timothy H Burgess; Nelson Michael; Edmund Tramont Journal: Mil Med Date: 2019-11-01 Impact factor: 1.437
Authors: Meredith S Shiels; Ruth M Pfeiffer; Mitchell H Gail; H Irene Hall; Jianmin Li; Anil K Chaturvedi; Kishor Bhatia; Thomas S Uldrick; Robert Yarchoan; James J Goedert; Eric A Engels Journal: J Natl Cancer Inst Date: 2011-04-11 Impact factor: 13.506
Authors: Meredith S Shiels; Ruth M Pfeiffer; H Irene Hall; Jianmin Li; James J Goedert; Lindsay M Morton; Patricia Hartge; Eric A Engels Journal: JAMA Date: 2011-04-13 Impact factor: 56.272
Authors: David C Boettiger; Caroline A Sabin; Andrew Grulich; Lene Ryom; Fabrice Bonnet; Peter Reiss; Antonella d'arminio Monforte; Ole Kirk; Andrew Phillips; Mark Bower; Gerd Fätkenheuer; Jens D Lundgren; Matthew Law Journal: AIDS Date: 2016-06-19 Impact factor: 4.177
Authors: Marie-Josèphe Horner; Steady Chasimpha; Adrian Spoerri; Jessie Edwards; Julia Bohlius; Hannock Tweya; Petros Tembo; Franklin Nkhambule; Eddie Moffo Phiri; William C Miller; Kennedy Malisita; Sam Phiri; Charles Dzamalala; Andrew F Olshan; Satish Gopal Journal: Clin Infect Dis Date: 2019-08-16 Impact factor: 9.079
Authors: Meredith S Shiels; Stephen R Cole; Joan S Chmiel; Joseph Margolick; Jeremy Martinson; Zuo-Feng Zhang; Lisa P Jacobson Journal: J Clin Epidemiol Date: 2009-10-31 Impact factor: 6.437
Authors: Meredith S Shiels; Eric A Engels; Martha S Linet; Christina A Clarke; Jianmin Li; H Irene Hall; Patricia Hartge; Lindsay M Morton Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-04-17 Impact factor: 4.254